The ATTRACTIVE 1 Trial - a First-in-human Phase I, Dose Escalating, Double-blind, Placebo-controlled, Single and Multiple Dose Trial of ATR-258 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Latest Information Update: 18 Mar 2024
At a glance
- Drugs ATR-258 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Acronyms ATTRACTIVE 1; The ATTRACTIVE 1 Trial
- Sponsors Atrogi
Most Recent Events
- 14 Mar 2024 Results presented in an Atrogi media release.
- 15 Dec 2023 Status changed from active, no longer recruiting to completed.
- 06 Oct 2023 Results of safety, tolerability, and pharmacokinetics of ATR-258 , presented at the 59th Annual Meeting of the European Association for the Study of Diabetes